- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00944424
Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca (GORG-002)
December 11, 2011 updated by: King Faisal Specialist Hospital & Research Center
GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer
Randomized phase III trial to determine the effectiveness of High dose versus Standard dose of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
2 Arms Randomization in patients with metastatic breast cancer.
Arm A = Docetaxel + High dose Vitamin D2
Arm B = Docetaxel + Standard dose Vitamin D2
Study Type
Interventional
Enrollment (Anticipated)
260
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Taher Tweigeri, MD
- Phone Number: 38047 0096614647272
- Email: ttwegieri@kfshrc.edu.sa
Study Contact Backup
- Name: Romelia Retuta
- Phone Number: 32957 966-1-4647272
- Email: romelia@kfshrc.edu.sa
Study Locations
-
-
-
Kuwait City, Kuwait
- Not yet recruiting
- Kuwait Cancer Center
-
-
-
-
-
Jeddah, Saudi Arabia
- Not yet recruiting
- King Abdulaziz Hospital and Oncology Center
-
Principal Investigator:
- Tarek Darwish, MD
-
Riyadh, Saudi Arabia
- Not yet recruiting
- King Fahad Medical City
-
Riyadh, Saudi Arabia
- Not yet recruiting
- King Abdulaziz Medical City
-
-
Central
-
Riyadh, Central, Saudi Arabia, 11211
- Recruiting
- King Faisal Specialist Hospital & Research Center
-
Principal Investigator:
- Taher Al-Tweigeri, MD
-
Principal Investigator:
- Dahish Ajarim, MD
-
Sub-Investigator:
- Adher Al-Sayed, MD
-
Sub-Investigator:
- Mohammad Al-Shabanah, MD
-
-
-
-
-
Al Ain City, United Arab Emirates
- Not yet recruiting
- Tawam Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Histologically proven metastatic adenocarcinoma of the breast.
- Gender: female.
- Age ≥18 years.
- ECOG performance status ≤ 2.(see appendix I)
- 25 (OH) Vitamin D level ≤ 100nmol/L (40ng/L).
- No more than 1 prior chemotherapy regimen not including Docetaxel or Paclitaxel for metastatic breast cancer.
- Patients progressed on Doxorubicin or epirubicin as first line for metastatic breast cancer is eligible.
- Concurrent bisphosphonate therapy allowed.
- Life expectancy more than 6 months
- At least 12 months since prior adjuvant or neo-adjuvant chemotherapy including Taxanes regimens.
- Adequate hematologic, hepatic and renal function.
- Written informed consent.
Exclusion Criteria:
- Pregnant or lactating women.
- Male breast cancer.
- Women of childbearing potential unless surgically sterile or using adequate measures of contraception.
- Metastatic inflammatory breast cancer.
- CNS metastasis.
- Leptomeningeal carcinomatosis.
- Malignant hypercalcemia.
- History of kidney stones.
- History of active primary hyperparathyroidism.
- Normal 25 (OH) Vitamin D level ≥100 nmol/L or ≥ 40 ng/L.
- Previous or concomitant malignancy of any type, except adequately treated basal cell carcinoma of the skin or in situ cervix cancer.
- Patient on any anti-Psychotic medications or Steroid therapy.
- History of malabsorption syndrome (pancreatic insufficiency, celiac disease and tropical sprue).
Any of the following abnormal baseline hematological values:
- ANC < 1.0 x109/L, or platelets < 100.000 x 109/L.
- Any of the following abnormal laboratory tests: total serum bilirubin >2.00 x ULN (upper limit of normal), AST, ALT > 2.5 x ULN or ALP >2.50 x ULN (upper limit of normal).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Arm A = Docetaxel + High dose Vitamin D2
|
Docetaxel + High dose Vitamin D2
|
Active Comparator: Arm B
Docetaxel + Standard dose Vitamin D2
|
Docetaxel + Standard dose Vitamin D2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to progression is from the start of Docetaxel to disease progression. Patients who have not progressed at the time of study completion or who are lost to follow-up are censored at the last Vitamin D administration date.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival is defined as the time from start of Docetaxel to death due to any cause. Patients for whom no death is captured on the clinical database are censored at the last date they were known to be alive.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Taher Al-Tweigeri, MD, KFSHRC
- Study Director: Dahish Ajarim, MD, KFSHRC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Anticipated)
July 1, 2012
Study Completion (Anticipated)
July 1, 2012
Study Registration Dates
First Submitted
July 22, 2009
First Submitted That Met QC Criteria
July 22, 2009
First Posted (Estimate)
July 23, 2009
Study Record Updates
Last Update Posted (Estimate)
December 13, 2011
Last Update Submitted That Met QC Criteria
December 11, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Micronutrients
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Docetaxel
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
Other Study ID Numbers
- RAC # 2091-009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Docetaxel + High dose Vitamin D2
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingVitamin D Deficiency | Chronic Kidney Disease 5D | Secondary Hyperparathyroidism Due to Renal CausesChina
-
University of Wisconsin, MadisonSanofi; Genzyme, a Sanofi CompanyTerminatedProstate CancerUnited States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedSystemic Lupus ErythematosusUnited States
-
Mansoura University Children HospitalCompletedPrematurity | Late-onset SepsisEgypt
-
Beijing Northland Biotech. Co., Ltd.CompletedAcute Myocardial InfarctionChina
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Texas Tech University Health Sciences CenterCompleted
-
Baylor College of MedicineNeuroMetrix, Inc.RecruitingPain | Neuropathy | Chemotherapy-induced Peripheral NeuropathyUnited States